{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:47:36Z","timestamp":1774957656553,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04130-4","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T08:50:31Z","timestamp":1758876631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association between the ApoB\/ApoA1 ratio and both the severity and mortality of metabolic dysfunction-associated fatty liver disease"],"prefix":"10.1186","volume":"25","author":[{"given":"Chao","family":"Fu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingqing","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dengxin","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"issue":"10290","key":"4130_CR1","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EP Elizabeth","year":"2021","unstructured":"Elizabeth EP, Vincent Wai-Sun W, Mary R. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(20)32511-3.","journal-title":"Lancet"},{"issue":"1","key":"4130_CR2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"E Mohammed","year":"2020","unstructured":"Mohammed E, Philip NN, Shiv KS, Quentin MA, Giovanni T, Manuel R-G, Shira Z-S, Vincent W-SW, Jean-Fran\u00e7ois D, J\u00f6rn MS, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039.","journal-title":"J Hepatol"},{"issue":"8","key":"4130_CR3","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.3390\/ijms22084156","volume":"22","author":"S Yoshitaka","year":"2021","unstructured":"Yoshitaka S, Naoto K, Toshimasa Y, Takashi K. Role of insulin resistance in MAFLD. Int J Mol Sci. 2021;22(8):4156. https:\/\/doi.org\/10.3390\/ijms22084156.","journal-title":"Int J Mol Sci"},{"key":"4130_CR4","doi-asserted-by":"publisher","unstructured":"Mohammed E, Arun JS, Jacob G. MAFLD: A Consensus-Driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 158(7):1999\u20132014.e1. https:\/\/doi.org\/10.1053\/j.gastro.2019.11.312","DOI":"10.1053\/j.gastro.2019.11.312"},{"issue":"0","key":"4130_CR5","doi-asserted-by":"publisher","first-page":"155999","DOI":"10.1016\/j.metabol.2024.155999","volume":"160","author":"Z Huai","year":"2024","unstructured":"Huai Z, Xiao-Dong Z, Michael DS, Gregory YHL, Herbert T, Luca V, Virend KS, Christopher DB, Giovanni T, Wah Y, et al. Global burden of metabolic diseases, 1990\u20132021. Metabolism. 2024;160(0):155999. https:\/\/doi.org\/10.1016\/j.metabol.2024.155999.","journal-title":"Metabolism"},{"issue":"1","key":"4130_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12933-024-02434-5","volume":"23","author":"Z Haixiang","year":"2024","unstructured":"Haixiang Z, Leonardo Antonio S, Eliano Pio N, Gavino C, Gianpaolo V. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review. Cardiovasc Diabetol. 2024;23(1):346. https:\/\/doi.org\/10.1186\/s12933-024-02434-5.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"4130_CR7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"EASL-EASD-EASO","year":"2024","unstructured":"EASL-EASD-EASO. Clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031.","journal-title":"J Hepatol"},{"issue":"23","key":"4130_CR8","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.3390\/nu14234969","volume":"14","author":"W Jing","year":"2022","unstructured":"Jing W, Shoumeng Y, Yani C, Feinan C, Meihua P, Weiwei C. The diagnostic and prognostic value of the Triglyceride-Glucose index in metabolic Dysfunction-Associated fatty liver disease (MAFLD): A systematic review and Meta-Analysis. Nutrients. 2022;14(23):4969. https:\/\/doi.org\/10.3390\/nu14234969.","journal-title":"Nutrients"},{"issue":"9","key":"4130_CR9","doi-asserted-by":"publisher","first-page":"e075413","DOI":"10.1136\/bmjopen-2023-075413","volume":"13","author":"Y Rong","year":"2023","unstructured":"Rong Y, Weijiang X, Hewei P, Lili L, Shuo Y, Shanghua X, Zhijian H, Xian-E P. Diagnostic value of triglyceride-glucose index and related parameters in metabolism-associated fatty liver disease in a Chinese population: a cross-sectional study. BMJ Open. 2023;13(9):e075413. https:\/\/doi.org\/10.1136\/bmjopen-2023-075413.","journal-title":"BMJ Open"},{"issue":"1","key":"4130_CR10","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12933-024-02343-7","volume":"23","author":"C Qingling","year":"2024","unstructured":"Qingling C, Pingping H, Xiaoxue H, Ye S, Mengfan J, Linya P, Zixing D, Xizhi Y, Rui L, Yuwen L, et al. Association between triglyceride-glucose related indices and mortality among individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease. Cardiovasc Diabetol. 2024;23(1):232. https:\/\/doi.org\/10.1186\/s12933-024-02343-7.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"4130_CR11","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","volume":"42","author":"P Barton","year":"2022","unstructured":"Barton P, Francine D, Michael KW, Alan M, Gmerice C, Zahid H, David A, Jay EC, Gregg DH, Peter SP. Nonalcoholic fatty liver disease and cardiovascular risk: A scientific statement from the American heart association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168\u201385. https:\/\/doi.org\/10.1161\/ATV.0000000000000153.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"4130_CR12","doi-asserted-by":"publisher","first-page":"e3295","DOI":"10.1210\/clinem\/dgac283","volume":"107","author":"H Hangkai","year":"2022","unstructured":"Hangkai H, Yanjun G, Zhening L, Yan Z, Yishu C, Chengfu X. Remnant cholesterol predicts Long-term mortality of patients with metabolic Dysfunction-associated fatty liver disease. J Clin Endocrinol Metab. 2022;107(8):e3295\u2013303. https:\/\/doi.org\/10.1210\/clinem\/dgac283.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"4130_CR13","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","volume":"4","author":"DS Allan","year":"2019","unstructured":"Allan DS, George T, Tamara G, Ann Marie N, Michael P, Alberico C, Brian AF. Apolipoprotein B particles and cardiovascular disease: A narrative review. JAMA Cardiol. 2019;4(12):1287\u201395. https:\/\/doi.org\/10.1001\/jamacardio.2019.3780.","journal-title":"JAMA Cardiol"},{"issue":"25","key":"4130_CR14","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000625","volume":"139","author":"MG Scott","year":"2018","unstructured":"Scott MG, Neil JS, Alison LB, Craig B, Kim KB, Roger SB, Lynne TB, Sarah dF, Joseph F-T, Daniel EF, et al. The management of blood cholesterol: A report of the American college of cardiology\/american heart association task force on clinical practice guidelines. Circulation. 2018;139(25):e1082\u2013143. https:\/\/doi.org\/10.1161\/CIR.0000000000000625. AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on.","journal-title":"Circulation"},{"issue":"10","key":"4130_CR15","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41569-024-01039-5","volume":"21","author":"AF Brian","year":"2024","unstructured":"Brian AF, Eugene B, Alberico LC. The LDL cumulative exposure hypothesis: evidence and practical applications. Nat Rev Cardiol. 2024;21(10):701\u201316. https:\/\/doi.org\/10.1038\/s41569-024-01039-5.","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"4130_CR16","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41569-021-00613-5","volume":"19","author":"M Anurag","year":"2021","unstructured":"Anurag M, Michael DS. Apolipoproteins in vascular biology and atherosclerotic disease. Nat Rev Cardiol. 2021;19(3):168\u201379. https:\/\/doi.org\/10.1038\/s41569-021-00613-5.","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"4130_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa1001689","volume":"364","author":"VK Amit","year":"2011","unstructured":"Amit VK, Marina C, Margarita dlL-M, Amrith R, Megan FB, Kashif J, Benjamin CF, Julie AP, Megan LM, Robert LW, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364(2):127\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1001689.","journal-title":"N Engl J Med"},{"issue":"1","key":"4130_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12933-024-02140-2","volume":"23","author":"F Chao","year":"2024","unstructured":"Chao F, Dongbo L, Qi L, Xuedong W, Xiaoxue M, Hong P, Shi F, Zhao S, Weishen Q, Mengyue Y, et al. Revisiting an old relationship: the causal associations of the ApoB\/ApoA1 ratio with cardiometabolic diseases and relative risk factors-a Mendelian randomization analysis. Cardiovasc Diabetol. 2024;23(1):51. https:\/\/doi.org\/10.1186\/s12933-024-02140-2.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"4130_CR19","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ER Mary","year":"2023","unstructured":"Mary ER, Jeffrey VL, Vlad R, Sven MF, Arun JS, Fasiha K, Diana R, Manal FA, Quentin MA, Juan Pablo A, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542\u201356. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003.","journal-title":"J Hepatol"},{"issue":"4","key":"4130_CR20","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"A Paul","year":"2007","unstructured":"Paul A, Jason MH, Giulio M, Ellisabetta B, Jacob G, Geoffrey CF, Felicity E, Sushma S, Alastair DB, John PB, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846\u201354. https:\/\/doi.org\/10.1002\/hep.21496.","journal-title":"Hepatology"},{"issue":"6","key":"4130_CR21","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.2337\/dc09-2110","volume":"33","author":"JA Karlee","year":"2010","unstructured":"Karlee JA, Edward JB, George NI. Insulin resistance predicts mortality in nondiabetic individuals in the U.S. Diabetes Care. 2010;33(6):1179\u201385. https:\/\/doi.org\/10.2337\/dc09-2110.","journal-title":"Diabetes Care"},{"issue":"3","key":"4130_CR22","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1001\/jamacardio.2021.5083","volume":"7","author":"AM Nicholas","year":"2021","unstructured":"Nicholas AM, Robert PG, Giorgio EMM, Jeong-Gun P, Valerie M, Michael AB, Brian F, Evan S, Erik SS, Eugene B, et al. Association of Apolipoprotein B-Containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: distinguishing between particle concentration, type, and content. JAMA Cardiol. 2021;7(3):250\u20136. https:\/\/doi.org\/10.1001\/jamacardio.2021.5083.","journal-title":"JAMA Cardiol"},{"issue":"2","key":"4130_CR23","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1161\/CIRCRESAHA.123.323100","volume":"135","author":"K Vishal","year":"2024","unstructured":"Vishal K, Tse WWH, Ainara GC, Yi H, Farah K, Masami S-A, Jenny EK, Janet S-B, Edward AF, Baohai S, et al. Imbalance of APOB lipoproteins and large HDL in type 1 diabetes drives atherosclerosis. Circ Res. 2024;135(2):335\u201349. https:\/\/doi.org\/10.1161\/CIRCRESAHA.123.323100.","journal-title":"Circ Res"},{"issue":"20","key":"4130_CR24","doi-asserted-by":"publisher","first-page":"e025858","DOI":"10.1161\/JAHA.122.025858","volume":"11","author":"G Tamara","year":"2022","unstructured":"Tamara G, George T, Jacqueline dG, Patrick C, Robert AH, Allan DS. Physiological bases for the superiority of Apolipoprotein B over Low-Density lipoprotein cholesterol and Non-High-Density lipoprotein cholesterol as a marker of cardiovascular risk. J Am Heart Assoc. 2022;11(20):e025858. https:\/\/doi.org\/10.1161\/JAHA.122.025858.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"4130_CR25","doi-asserted-by":"publisher","first-page":"H76","DOI":"10.1152\/ajpheart.00708.2019","volume":"319","author":"M Antonella","year":"2020","unstructured":"Antonella M, Erika S, Santo M. The effects of exercise training on lipid metabolism and coronary heart disease. Am J Physiol Heart Circ Physiol. 2020;319(1):H76\u201388. https:\/\/doi.org\/10.1152\/ajpheart.00708.2019.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"12","key":"4130_CR26","doi-asserted-by":"publisher","first-page":"108634","DOI":"10.1016\/j.jdiacomp.2023.108634","volume":"37","author":"P Ioana","year":"2023","unstructured":"Ioana P, Andrada Doina M, Simona \u0218, Anca P-S, Cristian S. Comparative evaluation of LDL-CT, non-HDL\/HDL ratio, and ApoB\/ApoA1 in assessing CHD risk among patients with type 2 diabetes mellitus. J Diabetes Complications. 2023;37(12):108634. https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108634.","journal-title":"J Diabetes Complications"},{"issue":"2","key":"4130_CR27","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jacl.2015.11.017","volume":"10","author":"Y Moon Hee","year":"2016","unstructured":"Moon Hee Y, Jidong S, Geum-Youn G. The associations between Apolipoprotein B, A1, and the B\/A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population. J Clin Lipidol. 2016;10(2):289\u201398. https:\/\/doi.org\/10.1016\/j.jacl.2015.11.017.","journal-title":"J Clin Lipidol"},{"issue":"6","key":"4130_CR28","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/labmed\/lmad021","volume":"54","author":"P Kyoung-Jin","year":"2023","unstructured":"Kyoung-Jin P. Associations between Apolipoprotein B\/A1 ratio, lipoprotein(a), and the risk of metabolic-associated fatty liver diseases in a Korean population. Lab Med. 2023;54(6):633\u20137. https:\/\/doi.org\/10.1093\/labmed\/lmad021.","journal-title":"Lab Med"},{"issue":"0","key":"4130_CR29","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.2147\/DMSO.S433876","volume":"16","author":"C Yan","year":"2023","unstructured":"Yan C, Shengyue C, Yuanyuan H, Qing X, Xin Z. Elevated ApoB\/apoA-1 is associated with in-Hospital mortality in elderly patients with acute myocardial infarction. Diabetes Metab Syndr Obes. 2023;16(0):16:3501\u201312. https:\/\/doi.org\/10.2147\/DMSO.S433876.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"4130_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.annepidem.2011.08.008","volume":"22","author":"S Oleg","year":"2011","unstructured":"Oleg S, Odd N, Andrej MG. Determinants of cardiovascular and all-cause mortality in Northwest russia: a 10-year follow-up study. Ann Epidemiol. 2011;22(1):57\u201365. https:\/\/doi.org\/10.1016\/j.annepidem.2011.08.008.","journal-title":"Ann Epidemiol"},{"issue":"12","key":"4130_CR31","doi-asserted-by":"publisher","first-page":"5669","DOI":"10.1111\/dom.15935","volume":"26","author":"P Miriam","year":"2024","unstructured":"Miriam P, Mark W, Peder AG, Stephen H, Pavel H, Giuseppe M, Michel M, Neil P, John C, Katie H. Lipids and apolipoproteins and the risk of vascular disease and mortality outcomes in women and men with type 2 diabetes in the ADVANCE study. Diabetes Obes Metab. 2024;26(12):5669\u201380. https:\/\/doi.org\/10.1111\/dom.15935.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"4130_CR32","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1007\/s13524-018-0707-2","volume":"55","author":"TL Joseph","year":"2018","unstructured":"Joseph TL, Robert AH, Richard GR. Cigarette smoking and All-Cause and Cause-Specific adult mortality in the united States. Demography. 2018;55(5):1855\u201385. https:\/\/doi.org\/10.1007\/s13524-018-0707-2.","journal-title":"Demography"},{"issue":"1","key":"4130_CR33","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1186\/s12889-023-17421-w","volume":"23","author":"Z Liang","year":"2023","unstructured":"Liang Z, Yonghong M, Ke M, Chao L, Zhuo Z, Guoshuai S. Tobacco smoke and all-cause mortality and premature death in china: a cohort study. BMC Public Health. 2023;23(1):2486. https:\/\/doi.org\/10.1186\/s12889-023-17421-w.","journal-title":"BMC Public Health"},{"issue":"0","key":"4130_CR34","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/1741-7015-11-195","volume":"11","author":"NS Sandra","year":"2013","unstructured":"Sandra NS, Jana V, vV-O, Judith MV, Marike H, Robin B, Anneke PFD, Muller C, Edith K, Andr\u00e9 JF, vB P, Melanie M, vdK. Bruce H R W: associations between smoking, components of metabolic syndrome and lipoprotein particle size. BMC Med. 2013;11(0):195. https:\/\/doi.org\/10.1186\/1741-7015-11-195.","journal-title":"BMC Med"},{"issue":"5","key":"4130_CR35","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.cmet.2024.04.006","volume":"36","author":"B Tao","year":"2024","unstructured":"Tao B, Ling G, Zhenyu Y, Shanshan S, Xuemin W, Christopher GP, Jiajun Z. Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease. Cell Metab. 2024;36(5):947\u201368. https:\/\/doi.org\/10.1016\/j.cmet.2024.04.006.","journal-title":"Cell Metab"},{"issue":"11","key":"4130_CR36","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.3390\/ijms25115640","volume":"25","author":"P Piero","year":"2024","unstructured":"Piero P, Mohamad K, Laura M, Valeria P, Valeria I, Annarita G, Gyorgy B, Agostino DC. Metabolic Dysfunction-Associated steatotic liver disease: from pathogenesis to current therapeutic options. Int J Mol Sci. 2024;25(11):5640. https:\/\/doi.org\/10.3390\/ijms25115640.","journal-title":"Int J Mol Sci"},{"issue":"18","key":"4130_CR37","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.3390\/nu15183970","volume":"15","author":"Y Keungmo","year":"2023","unstructured":"Keungmo Y, Myeongjun S. New insights into the pathogenesis of Metabolic-Associated fatty liver disease (MAFLD): Gut-Liver-Heart crosstalk. Nutrients. 2023;15(18):3970. https:\/\/doi.org\/10.3390\/nu15183970.","journal-title":"Nutrients"},{"issue":"3","key":"4130_CR38","doi-asserted-by":"publisher","first-page":"101372","DOI":"10.1016\/j.gendis.2024.101372","volume":"12","author":"H Shuwei","year":"2025","unstructured":"Shuwei H, Yingjie A, Chencheng H, Fathima NCB, Yanyong X. Transcription factors, metabolic dysfunction-associated fatty liver disease, and therapeutic implications. Genes Dis. 2025;12(3):101372. https:\/\/doi.org\/10.1016\/j.gendis.2024.101372.","journal-title":"Genes Dis"},{"issue":"1","key":"4130_CR39","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11892-008-0011-4","volume":"8","author":"A Martin","year":"2008","unstructured":"Martin A, Marja-Riitta T, Jan B. Fatty liver, insulin resistance, and dyslipidemia. Curr Diab Rep. 2008;8(1):60\u20134. https:\/\/doi.org\/10.1007\/s11892-008-0011-4.","journal-title":"Curr Diab Rep"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04130-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04130-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04130-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T08:50:32Z","timestamp":1758876632000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04130-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4130"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04130-4","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"25 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All survey protocols were approved by the institutional review board of the National Center for Health Statistics. The research adhered to the Declaration of Helsinki and received approval from the Ethics Committee of the PLA General Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"650"}}